跳转至内容
Merck
CN

B1170000

白消安

European Pharmacopoeia (EP) Reference Standard

登录查看公司和协议定价

别名:
白消安, 1,4-丁二醇二甲烷磺酸盐
线性分子式:
CH3SO2O(CH2)4OSO2CH3
CAS号:
分子量:
246.30
Beilstein:
1791786
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

busulfan

制造商/商品名称

EDQM

mp

114-117 °C (lit.)

应用

pharmaceutical (small molecule)

格式

neat

SMILES字符串

CS(=O)(=O)OCCCCOS(C)(=O)=O

InChI

1S/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3

InChI key

COVZYZSDYWQREU-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

本品按现行药典规定交付。所有为支持本产品而提供的信息,包括SDS和任何产品信息单均由药典颁发机构制定并发布。 如需进一步信息和支持,请访问现行药典网站。

应用

白消安EP 参考标准品设计用于欧洲药典规定的实验室测试。

包装

本品按照现行药典要求提供。有关当前单位数量,请见EDQM 参考目录

其他说明

可能适用相应的销售限制。

相关产品

产品编号
说明
价格

象形图

Skull and crossbonesHealth hazard

警示用语:

Danger

危险分类

Acute Tox. 3 Oral - Carc. 1A - Muta. 1B - Repr. 1B

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Arnon Nagler et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(28), 3549-3556 (2013-08-28)
Cyclophosphamide (Cy) combined with total-body irradiation (TBI) or with busulfan (Bu) are currently the most common myeloablative regimens used in allogeneic stem-cell transplantation (alloSCT) in adults with acute myelogenous leukemia (AML). Intravenous (IV) Bu has more predictable bioavailability and a
Je-Hwan Lee et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(6), 701-709 (2012-11-07)
We conducted a phase III randomized clinical trial to compare two myeloablative conditioning regimens for allogeneic hematopoietic cell transplantation (HCT) in patients with leukemia and myelodysplastic syndrome. After randomization, 64 patients received busulfan (3.2 mg/kg per day × 4 days)
Christopher Bredeson et al.
Blood, 122(24), 3871-3878 (2013-10-02)
We conducted a prospective cohort study testing the noninferiority of survival of ablative intravenous busulfan (IV-BU) vs ablative total body irradiation (TBI)-based regimens in myeloid malignancies. A total of 1483 patients undergoing transplantation for myeloid malignancies (IV-BU, N = 1025;
Edward A Copelan et al.
Blood, 122(24), 3863-3870 (2013-09-26)
Cyclophosphamide combined with total body irradiation (Cy/TBI) or busulfan (BuCy) are the most widely used myeloablative conditioning regimens for allotransplants. Recent data regarding their comparative effectiveness are lacking. We analyzed data from the Center for International Blood and Marrow Transplant
M Hassan
Medical oncology (Northwood, London, England), 16(3), 166-176 (1999-10-19)
High-dose busulfan is an important component in many conditioning protocols for hematopoietic stem cell transplantation (HSCT) or bone marrow transplantation (BMT) in both adults and children. During the past 12y several studies have reported the wide inter-individual variability in busulfan

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门